63 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
7 May 24
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
7:39am
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts
8-K
EX-1.1
rnzfvr7m0g
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
424B5
hy3njlc3hv
13 Mar 24
Prospectus supplement for primary offering
4:04pm
424B5
b5xamcgo3kde kiuhi1o
11 Mar 24
Prospectus supplement for primary offering
4:06pm
424B4
10uwkdzgcba38i
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-99.1
bwchqa
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
wm7o14jb2pbtgalx62qd
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
x8imjxi3u1p367m3bvj
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
lyb40ncj
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
ateed0aa7i7h60asjbe
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.2
e3duqb0qimjkes
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
hsj9f95sryzen 54
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am